Business Context and Reporting Period
This Form 8-K is filed by Fluidigm Corporation (not Standard BioTools Inc.) on February 10, 2014. The report addresses an adjustment to previously reported financial results for the quarter and year ended December 31, 2013, due to final determinations of executive and employee bonus awards.
Key Financial Metrics and Adjustments
The filing details an increase in total costs and expenses of $703,654, including a $123,626 increase in cost of product revenue. This adjustment revises the net loss and loss per share (EPS) as follows:
- Quarter Ended Dec 31, 2013: Net loss increased from $3.9 million to $4.6 million; EPS increased from $0.15 to $0.18.
- Year Ended Dec 31, 2013: Net loss increased from $15.8 million to $16.5 million; EPS increased from $0.62 to $0.65.
The filing does not provide updated figures for revenue, cash flow, margins, debt, or liquidity.
Material Changes Versus Prior Period
The material change is solely the restatement of expenses and net loss due to the Compensation Committee exercising discretion to approve bonus awards exceeding previously established targets. The increase in expenses is attributed to the Executive Bonus Plan and an increased aggregate bonus pool under the Employee Bonus Plan.
Management Commentary and Compensatory Arrangements
Management exercised discretion under the Executive Bonus Plan to award bonuses based on 2013 corporate performance. Specific awards approved for executive officers include:
- Gajus Worthington (CEO): $297,500
- Vikram Jog (CFO): $155,800
- William M. Smith (EVP, Legal): $156,000
- Fredric Walder (COO): $152,400
- Robert Jones (EVP, R&D): $154,050
- Mai Chan (Grace) Yow (EVP, Manufacturing): $148,100
For the 2014 performance period, the CEO's base salary was set at $490,000 with a target bonus of 70%. Other executives have target bonuses set at 42.5% of their respective base salaries.
Investor Verification Checklist
- Verify the updated financial statements in the upcoming Form 10-K for the year ended December 31, 2013.
- Confirm the impact of the $703,654 expense increase on the company's cash position and working capital.
- Review the specific performance metrics used by the Compensation Committee to justify bonuses exceeding targets.
- Monitor future filings for any further adjustments to 2013 results or changes to 2014 compensation targets.